Letifend

RSS

Canine leishmaniasis vaccine (recombinant protein)

Authorised
This medicine is authorised for use in the European Union.

Overview

This is a summary of the European public assessment report (EPAR) for Letifend.It explains how the Agency assessed this veterinary medicine to recommend its authorisation in the European Union (EU) and its conditions of use. It is not intended to provide practical advice on how to use Letifend.

For practical information about using Letifend, animal owners or keepers should read the package leaflet or contact their veterinarian or pharmacist.

This EPAR was last updated on 22/02/2022

Authorisation details

Product details
Name
Letifend
Agency product number
EMEA/V/C/003865
Active substance
Recombinant protein Q from Leishmania infantum MON-1
International non-proprietary name (INN) or common name
Canine leishmaniasis vaccine (recombinant protein)
Species
Dogs
Anatomical therapeutic chemical veterinary (ATCvet) codes
QI07A
Publication details
Marketing-authorisation holder
LETI Pharma, S.L.U.
Revision
11
Date of issue of marketing authorisation valid throughout the European Union
20/04/2016
Contact address

C/ Del Sol 5
Poligono Industrial Norte
Tres Cantos
28760 Madrid
Spain

Product information

18/02/2022 Letifend - EMEA/V/C/003865 - IB/0027

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.

 

Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Inactivated bacterial vaccines (including mycoplasma, toxoid and chlamydia)

Therapeutic indication

For active immunisation of dogs from 6 months of age to reduce the risk of developing a clinical case of leishmaniasis.

Assessment history

How useful was this page?

Add your rating
Average
3 ratings